The pharmacokinetics of a single oral dose of a test formulation, estradiol valerate tablets (1 mg, manufactured by Zhejiang Aisheng Pharmaceutical Co., Ltd.), compared to a reference formulation, estradiol valerate tablets (1 mg, manufactured by DELPHARM Lille S.A.S.), were investigated in healthy female volunteers. The bioequivalence of the two formulations was evaluated. The safety of the test and reference formulations was observed in healthy Chinese volunteers.

Start Date07 Sep 2025

Sponsor / Collaborator

Zhejiang Aisheng Pharmaceutical Co. Ltd.

CTR20253175

/ Active, not recruitingNot Applicable

戊酸雌二醇片在健康人群中的生物等效性试验

[Translation] Bioequivalence study of estradiol valerate tablets in healthy subjects

[Translation]

Start Date15 Aug 2025

Sponsor / Collaborator

Zhejiang Aisheng Pharmaceutical Co. Ltd.

100 Clinical Results associated with Estradiol Valerate

100 Translational Medicine associated with Estradiol Valerate

100 Patents (Medical) associated with Estradiol Valerate

1,825

Literatures (Medical) associated with Estradiol Valerate

31 Dec 2025·GYNECOLOGICAL ENDOCRINOLOGY

Changes in menopause-specific quality of life between women with transdermal estradiol versus oral estrogens: results of a randomized controlled trial

Article

Author: Ruan, Xiangyan ; Tang, Ruiyi ; Yang, Xin ; Shu, Kuanyong ; Yu, Qi ; Xie, Meiqing ; Fan, Yubo ; Lv, Shulan ; Ren, Mulan ; Shi, Huirong ; Wu, Jie ; Chen, Rong ; Zhang, Zhifen

OBJECTIVE:

To compare the efficacy of oral and transdermal estrogens in improving the quality of life in perimenopausal and recently postmenopausal women.

METHODS:

257 women aged 40-55 years, within three years after their final menstrual period were randomized to receive transdermal oestrogel (t-E2) (n = 128) or oral estradiol valerate (o- E2V) (n = 129; both with micronized progesterone 200 mg for 14 days each month). Menopausal symptoms were recorded at screening and at 4, 12, and 24 weeks post-randomization. Menopausal symptoms were evaluated using the Menopause-Specific Quality of Life (MENQOL) questionnaire.

RESULTS:

Significant improvements of MENQOL scores were observed in both groups compared with baseline. The decrease of MENQOL scores after treatment showed almost no difference between the two groups (p > 0.05) except the VMS domain which indicated a better result in oral estrogen group after 24 weeks.

CONCLUSIONS:

This study showed that both transdermal and oral estrogens were highly effective in relieving the overall menopausal symptoms for recently-menopausal women, with little difference in treatment efficacy between the two routes.

01 Nov 2025·JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Inducing agents and PCOS - A comprehensive analysis

Review

Author: Shanmugam, Rajeshkumar ; Kumar, Jayalakshmi ; Muthukumaran, Dhanyaa

Polycystic Ovary Syndrome (PCOS) is a severe and heterogeneous endocrine disorder affecting 6-20 % of women of reproductive age globally. Despite its high prevalence, the underlying etiology and pathophysiology remain unclear, necessitating the use of animal models to study disease mechanisms and therapeutic targets. This review critically evaluates various induction agents used in PCOS animal models and their ability to mimic the clinical, metabolic, and reproductive manifestations of the human condition. Induction agents explored include androgens [Testosterone, Dihydrotestosterone (DHT), Dehydroepiandrosterone (DHEA)], estrogen (estradiol valerate), aromatase inhibitors (letrozole), endocrine disruptors (bisphenol A), and dietary modifications (high-fat or high-sugar diets). These agents, administered in species such as rats, mice, zebrafish, reproduce hallmark PCOS features, including hyperandrogenism, anovulation, polycystic ovaries, and insulin resistance. The review highlights the mechanisms, symptom profiles, and translational relevance of each model. Comparative analysis is provided to assess the strengths and limitations associated with each agent, considering factors such as hormonal balance, metabolic function, and reproductive outcomes. Animal models serve as essential tools for understanding PCOS and testing therapeutic interventions. Each inducing agent offers unique insights into specific aspects of the disorder, although none fully replicates the human syndrome. The selection of the agent and animal species based on research goals is vital for clinical relevance. Future work should focus on integrating models that reflect both reproductive and metabolic features of PCOS to improve translational value.

01 Nov 2025·REPRODUCTIVE BIOMEDICINE ONLINE

Impact of hormone replacement therapy on serum thyroid-stimulating hormone: a retrospective analysis

Article

Author: Cozzolino, Mauro ; Molinaro, Pietro ; Fasulo, Diego D ; Galliano, Daniela ; Pellicer, Antonio ; Mariani, Giulia ; Pellegrini, Livia

RESEARCH QUESTION:

What is the impact of hormone replacement therapy (HRT) on serum thyroid-stimulating hormone (TSH) during endometrial preparation for single-embryo transfer (SET)?

DESIGN:

This retrospective cohort study included 516 women (≤49 years) who underwent SET with either autologous or donor oocytes, between January 2022 and January 2023 at IVI Rome. TSH was measured at baseline (T₀), during endometrial thickness assessment (T₁), on embryo transfer day (T₂), and at the pregnancy test (T₃). TSH >2.5 mU/l was treated with levothyroxine. HRT consisted of oral estradiol valerate (6 mg/day) followed by vaginal progesterone (800 mg/day).

RESULTS:

TSH significantly increased at T₁ and T₃ compared to T₀ (TSH₀ 1.67 mU/l, 95%CI 1.59-1.74; TSH₁ 1.93 mU/l, 95%CI 1.83-2.04, p < 0.001; TSH₃ 2.08 mU/l, 95%CI 1.97-2.18, p < 0.001). Univariate analysis showed that patients with a TSH < 2.5 mU/l at T₃ had higher miscarriage rate (15.2%, 95%CI 10.8-20.6 vs 29.7%, 95%CI 19.7-41.4; p = 0.01) and lower ongoing pregnancy (65.8%, 95%CI 60-71.3 vs 49.5%, 95%CI 39.5-59.5; p = 0.005) and live birth rates (62.5%, 95%CI 56.3-68.3 vs 47.5%, 95%CI 37.3-57.8; p = 0.01). Multivariate analysis showed no significant association between TSH >2.5 mU/l and pregnancy (aOR 0.64, 95%CI 0.36-1.14, p=0.13) or miscarriage (aOR 1.78, 95%CI 0.87-3.66, p = 0.11), while negative association was observed between TSH >2.5 mU/l and live birth (aOR 0.54, 95%CI 0.32-0.92, p = 0.02).

CONCLUSIONS:

HRT significantly increased TSH concentrations. Additionally, a TSH >2.5 mU/l did not correlate with miscarriage, but it was significantly associated with lower live birth rates. Further studies are needed to clarify HRT's impact on thyroid function and reproductive outcomes.

News (Medical) associated with Estradiol Valerate

07 Jul 2025

·www.einpresswire.com

New Research Highlights Critical Role of Estradiol in Men’s Health

The importance of Estradiol Cannot Be Overlooked Estradiol levels are not solely a sexual health concern. Optimal estradiol levels are essential to men's health overall. ” — Chris Rue, FNP-C NEW ORLEANS, LA, UNITED STATES, July 7, 2025 / EINPresswire.com / -- [New Orleans, LA] – [07/07/2025] — While testosterone often receives the spotlight in discussions about men’s hormones, new research is drawing attention to estradiol, an estrogen hormone, as a vital component in male health. A growing body of scientific evidence reveals that estradiol is essential for men’s bone strength, cardiovascular health, sexual function, mood regulation, and metabolism — challenging the outdated notion that estrogen is only important in women. Estradiol: A Hidden Key to Male Health Estradiol (E2), the most potent form of estrogen, is produced in men primarily through the aromatization of testosterone. Though its levels are much lower in men than women, estradiol is anything but insignificant. According to a 2023 review published in Frontiers in Endocrinology, estradiol plays a foundational role in maintaining health and preventing disease in men, particularly as they age ( https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1229804/full ). “Estradiol is essential for men’s bone health, and its deficiency increases the risk of osteoporosis and fractures,” researchers noted. Cardiovascular and Metabolic Protection A 2022 study published in The Journal of Clinical Endocrinology & Metabolism found that men with low or excessively high estradiol levels had an increased risk of metabolic dysfunction and cardiovascular events. Maintaining optimal estradiol levels — typically between 20–40 pg/mL — may support healthier fat distribution and reduce the likelihood of developing type 2 diabetes or heart disease. Additionally, researchers from the University of Washington concluded that estradiol contributes to vascular function and endothelial health, noting that the hormone exerts anti-inflammatory effects that protect arterial integrity. ( https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625386/ ) Estradiol and Sexual Function Low estradiol levels can impair libido, erectile function, and sexual satisfaction, especially in men undergoing testosterone replacement therapy (TRT). A 2013 landmark study published in The New England Journal of Medicine demonstrated that both testosterone and estradiol are required for maintaining sexual health in men. ( https://www.nejm.org/doi/full/10.1056/NEJMoa1206168 ) This has prompted many hormone specialists to revise protocols for TRT, ensuring that estradiol levels are monitored and not inadvertently suppressed. Expert Insights and Clinical Implications “Estradiol is not just a byproduct of testosterone — it’s a vital hormone in its own right,” said Dr. Jonathan Ross, a hormone therapy researcher and author. “We need to update our clinical practices and educate men about the importance of estradiol screening, especially during hormone therapy.” New guidelines from hormone health organizations now recommend routine estradiol testing as part of any male hormone evaluation, particularly for those on TRT, aging men, or individuals with metabolic or bone health concerns. Chris Rue Metairie Optimal Performance Enhancement +1 504-265-5491 email us here Visit us on social media: LinkedIn Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

20 May 2025

·www.prnewswire.com

ESOC 2025: Combined oral contraceptives triple risk of cryptogenic stroke in young women, new study shows

HELSINKI, May 20, 2025 /PRNewswire/ -- New research presented today at the European Stroke Organisation Conference (ESOC) 2025 revealed that the use of combined oral contraceptives (OCs) is associated with a threefold increase in the risk of cryptogenic ischaemic stroke (CIS) in young women.(1) The findings add to a growing body of evidence linking hormonal contraception to vascular risk in women of reproductive age. Cryptogenic ischaemic stroke, which is stroke with no identifiable cause, accounts for up to 40% of all ischaemic strokes in young adults.(2) Despite its prevalence, the contribution of sex-specific risk factors, such as contraceptive use, has remained underexplored. While prior studies have associated combined OCs with stroke risk, this is among the few studies to focus specifically on cryptogenic stroke in young women. The Searching for Explanations for Cryptogenic Stroke in the Young (SECRETO) study included 268 women aged 18–49 years with CIS and 268 age-matched stroke-free controls across 14 centres in Europe. Of the participants, 66 patients and 38 controls were using combined OCs. After adjusting for age and established comorbidities such as hypertension, smoking, migraine with aura, and abdominal obesity, OC use was associated with an adjusted odds ratio of 3.00 (95% CI: 1.61–5.57). No significant interactions were found between OC use and these risk factors, suggesting that the increased stroke risk may operate independently of other known contributors. "Our findings confirm earlier evidence linking oral contraceptives to stroke risk," said Dr. Mine Sezgin, Department of Neurology, Istanbul University, and lead author of the study. "What's particularly notable is that the association remains strong even when accounting for other known risk factors, which suggests there may be additional mechanisms involved – possibly genetic or biological." Most OC users in the study were taking ethinylestradiol-based formulations, with a median dose of 20 micrograms. Other types of estrogen, such as estradiol hemihydrate and estradiol valerate, were also recorded. "We calculated the equivalent estrogen dose for each patient to ensure consistency," Dr Sezgin explained. "While our data provides important initial insights, larger studies are needed to determine if certain formulations carry different levels of risk. This knowledge could help guide more personalised contraceptive choices for women." While the researchers note that further prospective studies are needed, they advise clinicians to exercise caution when prescribing combined OCs to women with known vascular risk factors or a history of ischaemic stroke. "Our findings should prompt more careful evaluation of stroke risk in young women, particularly those with additional risk factors," concluded Dr. Sezgin. Moving forward, the researchers plan to explore biological and genetic mechanisms underlying the observed association between combined OC use and increased stroke risk to better understand how hormonal contraceptives may independently elevate stroke risk. Note to editors: A reference to ESOC 2025 must be included in all coverage and/or articles associated with this study. About the study author: Dr. Mine Sezgin is a neurologist and stroke researcher based at the Istanbul University Faculty of Medicine. Her work focuses on sex-specific risk factors and stroke prevention in young adults. About the European Stroke Organisation (ESO): The ESO is a pan-European society of stroke researchers and physicians, national and regional stroke societies and lay organisations that was founded in December 2007. The aim of the ESO is to reduce the burden of stroke by changing the way that stroke is viewed and treated. This can only be achieved by professional and public education, and by making institutional changes. ESO serves as the voice of stroke in Europe, harmonising stroke management across the whole of Europe and taking action to reduce the burden of stroke regionally and globally. References: 1. Sezgin, M., et al. Hormonal contraception increases the risk of cryptogenic stroke in young women. Abstract O049, presented at the European Stroke Organisation Conference; 21 May 2025; Vienna, Austria. 2. Yaghi, S., & Elkind, M. S. (2014). Cryptogenic stroke: A diagnostic challenge. Neurology. Clinical practice, 4(5), 386–393. SOURCE European Stroke Organisation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Result

23 Aug 2024

·pharma.economictimes.indiatimes.com

Govt bans 156 medicines including antibiotics, painkillers, multivitamins: Here is the full list

New Delhi: In a significant move aimed at safeguarding public health, the Indian government has banned 156 fixed-dose combination (FDC) drugs, including a variety of antibiotics, painkillers, multivitamins, and medications for treating fever and hypertension. This decision marks the largest crackdown on FDCs since 2016, when 344 such drugs were prohibited. The Union Ministry of Health and Family Welfare issued a gazette notification on Thursday, officially prohibiting the manufacture, sale, and distribution of the banned FDCs. The ban was based on the recommendations of an expert panel that reviewed a total of 324 FDCs. Impact on Pharmaceutical Industry The banned FDCs include popular combinations such as mefenamic acid and paracetamol injections, commonly used for pain relief and fever, and omeprazole magnesium with dicyclomine HCl, used to treat abdominal pain. The ban is expected to impact major pharmaceutical companies, including Sun Pharmaceuticals, Cipla, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, and Alkem Laboratories. Fixed Dose Combinations Drug Banned List Here is a table listing all 156 banned Fixed Dose Combinations (FDCs) SN Fixed Dose Combination (FDC) 1 Amylase + Protease + Glucoamylase + Pectinase + Alpha Galactosidase + Lactase + Beta-Gluconase + Cellulase + Lipase + Bromelain + Xylanase + Hemicellulase + Malt diastase + Invertase + Papain 2 Antimony Potassium Tartrate + Dried Ferrous Sulphate 3 Benfotiamine + Silymarin + L-Ornithine L-aspartate + Sodium Selenite + Folic acid + Pyridoxine hydrochloride 4 Bismuth Ammonium Citrate + Papain 5 Cyproheptadine HCl + Thiamine HCl + Riboflavine + Pyridoxine HCl + Niacinamide 6 Cyproheptadine Hydrochloride + Tricholine Citrate + Thiamine Hydrochloride + Riboflavine + Pyridoxine Hydrochloride 7 Rabeprazole Sodium (As enteric coated tablet) + Clidinium Bromide + Dicyclomine HCl + Chlordiazepoxide 8 Fungal Diastase + Papain + Nux vomica Tincture + Cardamom Tincture + Casein Hydrolysed + Alcohol 9 Mefenamic Acid + Paracetamol Injection 10 Omeprazole Magnesium + Dicyclomine HCl 11 S-adenosyl methionine + Metadoxine + Ursodeoxycholicacid BP + L-Methylfolate Calcium eq. to L- Methylfolate + Choline bitartratee + Silymarin + L-ornithine Laspartate + Inositol + Taurine 12 Silymarin + Thiamine Mononitrate + Riboflavin + Pyridoxine HCl + Niacinamide + Calcium pantothenate + Vitamin B12 13 Silymarin + Pyridoxine HCl + Cyanocobalamin + Niacinamide + Folic Acid 14 Silymarin + Vitamin B6 + Vitamin B12 + Niacinamide + Folic acid + Tricholine Citrate 15 Sodium Citrate + Citric Acid Monohydrate Flavored with Cardamom Oil, Caraway Oil, Cinnamon Oil, Clove Oil, Ginger Oil + Alcohol 16 Sucralfate + Acelofenac 17 Sucralfate + Domperidone + Dimethicone 18 Sucralfate + Domperidone 19 Tincture Ipecacuanha + Tincture Urgenia + Camphorated Opium Tincture + Aromatic Spirit of Ammonia + Chloroform + Alcohol 20 Ursodeoxycholic Acid + Metformin HCl 21 Weak Ginger tincture + Aromatic Spirit of Ammonia + Peppermint Spirit + Chloroform + Sodium Bicarbonate + Compound Cardamom + Alcohol 22 Sucralfate + Pantoprazole Sodium + Zinc Gluconate + Light Magnesium Carbonate 23 Aloe + Vitamin E Soap 24 Povidone Iodine+ Metronidazole + Aloe 25 Azelaic acid + Tea Tree Oil + Salicylic acid + Allantoin + Zinc oxide + Aloe vera + Jojoba oil + Vitamin E + Soap noodles 26 Azithromycin + Adapalene 27 Calamine + Aloes + Allantoin 28 Calamine + Diphenhydramine Hydrochloride + Aloe + Glycerine + Camphor 29 Chlorphenesin + Zinc oxide + Starch 30 Clindamycin Phosphate + Zinc acetate 31 Gamma Benzene Hexachloride + Benzocaine 32 Glucosamine hydrochloride + Diacerein + Menthol + Camphor + Capsaicin 33 Hydroxyquinone 2.0%w/w + Octyl Methoxycinnamate 5.0% w/w + Oxybenzone 30 % w/w 34 Ketoconazole +Zinc Pyrithione +D-Panthenol +Tea Tree Oil +Aloes 35 Ketoconazole +Aloe vera+ Vitamin A Acetate 36 Ketoconazole +Aloes + ZPTO 37 Kojic Acid +Arbutin +Octinoxate +Vitamin E + Mulberry 38 Lornoxicam +capsaicin +menthol+ camphor 39 Lornoxicam + Thiocolchicoside +Oleum Lini +Menthol + Methyl salicylate 40 Menthol + Aloe vera Topical Spray 41 Menthol +Lignocaine HCl +Aloe vera gel +Clotrimazole +Diphenhydramine 42 Miconazole nitrate + Gentamicin + Fluocinolone Acetonide +Zinc Sulphate 43 Miconazole +Tinidazole 44 Minoxidil +Aminexil+ Alcohol 45 Minoxidil +Azelaic acid + saw palmetto 46 Minoxidil +Aminexil 47 Pine Bark extract+ Kojic acid +Sodium Ascorbyl Phosphate 48 Povidone Iodine +Tinidazole +Zinc sulphate 49 Povidone Iodine + Ornidazole + Dexpanthenol 50 Salicyclic acid +Aloe vera+ Allantoin +D-Panthenol 51 Silver sulphadiazine +Chlorhexidine Gluconate solution +Allantoin + Aloe vera gel +Vitamin E acetate 52 Sodium salicylate + Zinc gluconate + Pyridoxine HCl 53 Tetracycline + Colistin Sulphate 54 Clomiphene +Ubidecarenone 55 Combikit of Clomiphene Citrate + Estradiol Valerate 56 Flavoxate HCl +Ofloxacin 57 Clomiphene Citrate +N-Acetylcysteine 58 Primerose Oil +Cod liver oil 59 Sildenafil Citrate +Papaverine +L-Arginine 60 Tranexamic acid +Mefenamic acid + Vitamin K1 61 Divalproex Sodium +Oxcarbazepine 62 Divalproex Sodium + Levetiracitam 63 Ergotamine tartrate +Caffeine + Paracetamol +Prochlorperazine maleate 64 Piracetam + Ginkgo biloba extracts + Vinpocetin 65 Ginkgo biloba + methylcobalamin 66 Ginkgo biloba + methylcobalamin + Alpha lipoic acid +Pyridoxine HCl 67 Ginseng Extract +Dried extract of Ginkgo Biloba 68 Meclizine HCl+ Paracetamol + Caffeine 69 Nicergoline + Vinpocetine 70 Gamma Linolenic Acid + Methylcobalamin 71 Beclomethasone Dipropionate + Neomycin Sulphate + Clotrimazole + Lignocaine HCl 72 Boric acid+ Phenylephrine HCl + Naphazoline Nitrate + Menthol + Camphor 73 Naphazoline HCl + Chlorpheniramine Maleate + Zinc Sulphate + Hydroxy Propyl Methyl Cellulose 74 Chlorpheniramine Maleate + Naphazoline HCl + Zinc Sulphate + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 75 Chlorpheniramine Maleate + Naphazoline HCl + Hydroxy Propyl Methyl Cellulose 76 Chlorpheniramine Maleate + Sodium Chloride + Boric Acid + Tetrahydrozoline HCl 77 Chlorpheniramine Maleate + Phenylephrine HCl + Antipyrine 78 Ketorolac Tromethamine + Chlorpheniramine Maleate + Phenylephrine HCl + Hydroxy Propyl Methyl Cellulose 79 Ketorolac Tromethamine + Flurometholone 80 Naphazoline HCl + Zinc Sulphate + Boric Acid + Sodium Chloride+ Chlorpheniramine Maleate 81 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Boric Acid + Borax + Menthol + Camphor 82 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Chlorpheniramine Maleate SN Fixed Dose Combination (FDC) 83 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Menthol + Camphor 84 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 85 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Methylparaben 86 Methenamine + Sodium Benzoate + Benzyl Alcohol 87 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 88 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate + Caffeine 89 Propoxyphene + Chlorpheniramine Maleate 90 Propoxyphene + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 91 Propoxyphene + Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride 92 Sodium Benzoate + Sodium Citrate + Citric Acid 93 Vitamin A Palmitate + Vitamin C + Vitamin E + Vitamin B6 + Vitamin B12 94 Vitamin A Palmitate + Vitamin C + Vitamin E + Niacinamide 95 Vitamin B6 + Vitamin B12 + Vitamin C 96 Vitamin B6 + Vitamin B12 + Niacinamide 97 Vitamin B12 + Vitamin B6 + Vitamin C + Folic Acid 98 Vitamin B12 + Vitamin B6 + Niacinamide + Folic Acid 99 Vitamin C + Vitamin E + Vitamin A + Niacinamide 100 Vitamin D + Calcium + Magnesium 101 Vitamin D + Calcium + Magnesium + Zinc 102 Calcium + Vitamin D + Vitamin K 103 Calcium + Vitamin D + Magnesium + Zinc 104 Calcium + Vitamin D + Vitamin K + Magnesium 105 Calcium + Vitamin D + Vitamin K + Magnesium + Zinc 106 Vitamin E + Vitamin A + Vitamin C + Niacinamide 107 Vitamin E + Vitamin A + Vitamin C + Folic Acid 108 Vitamin E + Vitamin A + Vitamin C + Biotin 109 Vitamin E + Vitamin A + Vitamin C + Vitamin B12 110 Vitamin E + Vitamin C + Folic Acid 111 Vitamin E + Vitamin C + Biotin 112 Vitamin E + Vitamin C + Vitamin B12 113 Vitamin E + Vitamin C + Zinc 114 Calcium + Vitamin D + Omega-3 Fatty Acids 115 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K 116 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Magnesium 117 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Zinc 118 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene 119 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene + Zinc 120 Vitamin C + Vitamin E + Beta-Carotene 121 Vitamin C + Vitamin E + Beta-Carotene + Zinc 122 Vitamin C + Vitamin E + Selenium 123 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids 124 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Magnesium 125 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Zinc 126 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Biotin 127 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 128 Vitamin E + Vitamin A + Vitamin C + Zinc 129 Vitamin E + Vitamin A + Vitamin C + Selenium 130 Vitamin E + Vitamin A + Vitamin C + Biotin 131 Vitamin E + Vitamin A + Vitamin C + Folic Acid + Niacinamide 132 Vitamin E + Vitamin C + Beta-Carotene + Zinc 133 Vitamin C + Vitamin E + Biotin + Folic Acid 134 Vitamin C + Vitamin E + Beta-Carotene + Folic Acid 135 Vitamin C + Vitamin E + Beta-Carotene + Selenium 136 Vitamin E + Vitamin C + Beta-Carotene + Biotin 137 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Biotin 138 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 139 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B12 140 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B6 141 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Folate 142 Calcium + Vitamin D + Magnesium + Vitamin K + Omega-3 Fatty Acids 143 Calcium + Vitamin D + Magnesium + Vitamin K + Biotin 144 Calcium + Vitamin D + Magnesium + Vitamin K + Selenium 145 Calcium + Vitamin D + Magnesium + Vitamin K + Vitamin B12 146 Calcium + Vitamin D + Magnesium + Vitamin K + Folate 147 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B6 148 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B12 149 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Folic Acid 150 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Biotin 151 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Selenium 152 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids 153 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Zinc 154 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Biotin 155 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Selenium 156 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Vitamin B12

Drug Approval

100 Deals associated with Estradiol Valerate

External Link

KEGG	Wiki	ATC	Drug Bank
D01413	Estradiol Valerate	G03CA03	DB13956

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Oestrogen deficiency	China	Hubei Huazhong Pharmaceutical Co. Ltd.	01 Jan 1983
Amenorrhea	Japan	Mochida Pharmaceutical Co., Ltd.	01 Nov 1954
Andropause	Japan	Mochida Pharmaceutical Co., Ltd.	01 Nov 1954
Dysmenorrhea	Japan	Mochida Pharmaceutical Co., Ltd.	01 Nov 1954
Hypomenorrhea	Japan	Mochida Pharmaceutical Co., Ltd.	01 Nov 1954
Infertility	Japan	Mochida Pharmaceutical Co., Ltd.	01 Nov 1954
Menorrhagia	Japan	Mochida Pharmaceutical Co., Ltd.	01 Nov 1954
Menstruation Disturbances	Japan	Mochida Pharmaceutical Co., Ltd.	01 Nov 1954
Metrorrhagia	Japan	Mochida Pharmaceutical Co., Ltd.	01 Nov 1954
Ovarian Diseases	Japan	Mochida Pharmaceutical Co., Ltd.	01 Nov 1954
Uterine Diseases	Japan	Mochida Pharmaceutical Co., Ltd.	01 Nov 1954
Hypoestrogenism	United States	PH HEALTH	15 Jul 1954
Prostatic Cancer	United States	PH HEALTH	15 Jul 1954
Vasomotor symptom	United States	PH HEALTH	15 Jul 1954
Vulvovaginal atrophy	United States	PH HEALTH	15 Jul 1954

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04036500 (CTgov)	Early Phase 1	-	11	Estradiol	ceckshnshw(lihvzrqzfw) = zjkuxvuteu trgexwsult (uojopqdlqs, 90) View more	-	01 Apr 2025
NCT04283656 (IDENTIFY, CTgov)	Phase 1	HIV Infections	8	Spironolactone 100mg+Estradiol 2mg+Doravirine/Lamivudine/Tenofovir (Treatment C)	xwuprwyndy(hyotwpupew) = ycserpvgza suqztribna (huaomfgoau, 21.7) View more	-	26 Mar 2025
				Doravirine/Lamivudine/Tenofovir (Treatment A)	xwuprwyndy(hyotwpupew) = sxhxctvjjl suqztribna (huaomfgoau, 41.75) View more
NCT04051320 (CTgov)	Phase 2	Depression, Postpartum \| Irritable Mood	23	Estradiol 2 Mg tablet+Micronized progesterone+Leuprolide Acetate 3.75 MG/ML (Hormone Sensitive Women (HS+))	ronjmidsbm(afjfbcrxsi) = wjxczbuxcv jrsrvltznx (knqatcybhn, 18.92) View more	-	25 Aug 2023
				Estradiol 2 Mg tablet+Micronized progesterone+Leuprolide Acetate 3.75 MG/ML (Hormone Insensitive Women (HS-))	ronjmidsbm(afjfbcrxsi) = ajqqltlise jrsrvltznx (knqatcybhn, 110.98) View more
NCT04865029 (CTgov)	Phase 2	COVID-19	10	Estradiol+Progesterone (Estradiol and Progesterone Arm)	fqlvysitht = uomhlyldxc rhtdeetwle (sefesfkzgu, ulmjwxjixi - zmnneflabh) View more	-	27 Jun 2023
				Folic Acid (Normal Saline and Folic Acid Arm)	fqlvysitht = oxkwsyyzyx rhtdeetwle (sefesfkzgu, bbrghfflwa - topbcturmo) View more
NCT03300518 (Pubmed \| Hum Reprod)	Not Applicable	-	552	Estrogen valerate pretreatment	mzrdpvngxs(awvzszdsaj) = dvgwciynsm amuuggqbkr (llojznmssg )	Negative	23 Apr 2022
				Estrogen valerate (Control group)	mzrdpvngxs(awvzszdsaj) = mtihpvnpeb amuuggqbkr (llojznmssg )
NCT04537078 (CTgov)	Phase 3	Infertility, Female	90	Gonadotropin+Decapeptyl+Cyclo-Progynova+progesterone+Duphaston (the Progestin Primed Double Stimulation Group)	oziguchkey(pjqhkffdko) = oqznzkgfff dsdkwxkrfs (aewyygddbo, mufterdqhx - nurqnmwlto) View more	-	17 Feb 2022
				Chorionic Gonadotropin+Cetrotide Injectable Product+Decapeptyl+Cyclo-Progynova+progesterone (the Flexible GnRh Antagonist)	edlmxymjdn(vjjwtptace) = wvbusotwlv gqfwpxtmln (vyuxoekstv, qanyypagfj - xcxgokvjid) View more
NCT01923298 (CTgov)	Phase 2	Breast Cancer \| Estrogen receptor positive breast cancer	14	Estradiol	ldkkfkwryf(qywauymbra) = omtlolnyzk ynrpeoxpbv (aguivbexae, nlwibvwzlq - bvfzukqqln) View more	-	04 Feb 2022
NCT02122198 (CTgov)	Not Applicable	Cognitive Dysfunction \| Endothelial dysfunction \| Impairment of Executive Functions	17	Placebo (Placebo)	drypvxynnu(awfanipghm) = lrdfoztdgx rwledwctal (gdfajzgtxi, 3.88) View more	-	10 Jan 2022
				Medroxyprogesterone+Estradiol+Leuprolide acetate (GnRH Agonist)	drypvxynnu(awfanipghm) = sftznkktwg rwledwctal (gdfajzgtxi, 57.61) View more
NCT03493126 (CTgov)	Phase 4	Vulvovaginal atrophy \| Perineal pain	59	Estradiol (Estradiol)	cuufaleshz(xmxsncxzlb) = vwuachqhkm mxjozcrugi (etwbuawvcp, 0.25) View more	-	22 Dec 2021
				Placebo (Placebo)	cuufaleshz(xmxsncxzlb) = idjeuexeye mxjozcrugi (etwbuawvcp, 0.22) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis